A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects

A Randomised, Single Centre, Double-blind, Incomplete Block Trial to Test for Equivalence Between Subcutaneous Injections of the GLP-1 Analogue NN9535 in 1 mg/ml, 3 mg/ml and 10 mg/ml Concentrations in Healthy Male Subject

This trial is conducted in Europe. The aim of this clinical trial is to investigate whether differences exist between three different concentrations of the drug, NN9535, administered in healthy male subjects in equal doses.

Inclusion Criteria:

• Healthy male subjects, based on an assessment of medical history, physical examination and clinical laboratory data at screening, as determined by the Investigator
• Body weight between 80 kg and 110 kg (both inclusive)
• Body Mass Index (BMI) between 18 and 27 kg/m2, both inclusive
• Fasting plasma glucose max 108 mg/dl (6.0 mmol/l)

Exclusion Criteria:

• Known or suspected allergy to trial product(s) or related products
• Previous participation in this trial (randomisation)
• The receipt of any investigational medicinal product within 3 months prior to this trial
• Subjects who have had a clinically relevant illness within 4 weeks of dosing
• History of or presence of cancer, diabetes, or any clinically relevant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders
• Regular smoking as defined by smoking 1 or more cigarettes or the equivalent amount of tobacco pr day, and unable to refrain from smoking during the entire confinement period